On the stock market since 2015, it operates in the world of health and science. It has 61 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $127.8M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
The net profit margin is 78% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 119% a year on average.
There is $191.0M in the vault; even if every debt were paid off, $127.8M would remain.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, ZVRA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ZVRA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.